Most patients and many doctors are unable to diagnose this condition, called a leg attack. But if not treated in time, it can cost you a li...

Stempeucel exhibits potent immuno-modulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to t...

"The US patent is for the method of treating ischemia by administering pooled allogeneic mesenchymal stromal cells," Stempeutics Research s...

The Nikkei share average ended down 0.2 per cent, or 49.66 points, to 21,378.73.

Founded in 2006 by Manipal Education and Medical Group (MEMG), Stempeutics later entered into an alliance with Cipla in 2009. It is an adva...

Another company which works in a similar space in India include Kasiak Research, which is a part of Bharat Serums and Vaccines (BSVL).

Stempeutics has received process patent from the Japan for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia.

Stempeutics' stem cell-based drugs enable living tissues to repair or replace tissue or organ function lost due to age, disease, damage or ...

At 09:40 a.m.; Cipla was trading 2.4 per cent higher at Rs 742.20. It hit a low of Rs 725 and a high of Rs 744.90 in trade today.

Backed by the Manipal Education and Medical Group and drug maker Cipla, Stempeutics makes stem cell-based drugs or regenerative medicine.